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Abstract
Background: Anti-apoptotic signals induced downstream of HER2 are known to contribute to the resistance to
current treatments of breast cancer cells that overexpress this member of the EGFR family. Whether or not some of
these signals are also involved in tumor maintenance by counteracting constitutive death signals is much less
understood. To address this, we investigated what role anti- and pro-apoptotic Bcl-2 family members, key
regulators of cancer cell survival, might play in the viability of HER2 overexpressing breast cancer cells.
Methods: We used cell lines as an in vitro model of HER2-overexpressing cells in order to evaluate how anti-
apoptotic Bcl-2, Bcl-xL and Mcl-1, and pro-apoptotic Puma and Bim impact on their survival, and to investigate
how the constitutive expression of these proteins is regulated. Expression of the proteins of interest was confirmed
using lysates from HER2-overexpressing tumors and through analysis of publicly available RNA expression data.
Results: We show that the depletion of Mcl-1 is sufficient to induce apoptosis in HER2-overexpressing breast
cancer cells. This Mcl-1 dependence is due to Bim expression and it directly results from oncogenic signaling, as
depletion of the oncoprotein c-Myc, which occupies regions of the Bim promoter as evaluated in ChIP assays,
decreases Bim levels and mitigates Mcl-1 dependence. Consistently, a reduction of c-Myc expression by inhibition
of mTORC1 activity abrogates occupancy of the Bim promoter by c-Myc, decreases Bim expression and promotes
tolerance to Mcl-1 depletion. Western blot analysis confirms that naïve HER2-overexpressing tumors constitutively
express detectable levels of Mcl-1 and Bim, while expression data hint on enrichment for Mcl-1 transcripts in these
tumors.
Conclusions: This work establishes that, in HER2-overexpressing tumors, it is necessary, and maybe sufficient, to
therapeutically impact on the Mcl-1/Bim balance for efficient induction of cancer cell death.
Background
Breast cancer is a heterogeneous disease, composed of
distinct entities with differing underlying pathogenic
processes. One such entity is the so-called HER2 sub-
type, which is characterized by amplification and/or
overexpression of this member of the human epidermal
growth factor receptor (HER) family. HER2 is an orphan
receptor with intrinsic tyrosine kinase activity [1] whose
activation results from the dynamic heterodimerization
of HER receptors members [2]. This activates a large
repertoire of transforming signaling molecules and
pathways that are, to a great extent, shared by HER
members.
Excess HER2 signaling leads to numerous oncogenic
processes, including cell proliferation and survival [1]. The
major signaling pathways activated by HER2 include the
RAS-Raf1-Mek-Erk and the PI3K-Akt pathways. Akt sig-
naling leads to mTOR activation. The mTOR signaling
complex 1 (mTORC1) helps maintaining protein synthesis
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eukaryotic initiation factor (eIF) 4E-binding proteins (4E-
BPs) and ribosomal protein S6 kinases (S6Ks) [3] that reg-
ulate the activity of EIF4F, a heterotrimeric complex
required for the cap-dependent ribosome recruitment
phase of translation initiation.
Activation of the Ras-MAPK-Erk and PI3K-Akt-
mTOR pathways both culminate in activation of tran-
scriptional programs, as well as cyclin dependant
kinases, that lead to progression through the cell cycle.
Current evidence indicates that, through either of these
pathways, HER2 signaling can regulate c-Myc, a multi-
functional transcription factor involved in cell cycle pro-
gression (see [4] and references therein). In particular,
mTORC1 activity might contribute to cell cycle progres-
sion in HER2 overexpressing cells, as c-Myc expression
is critically dependent upon EIF4F activity in cells with
high Akt activity [5,6]. Consistent with this, inhibition of
mTORC1 by RAD001 (everolimus) potently inhibits cell
cycle progression of HER2 overexpressing breast cancer
cells [7].
In addition to their deregulated proliferation, HER2
overexpressing cells exhibit altered survival signals.
Breast cancer cells overexpressing HER2 are resistant to
an array of cytotoxic agents and radiation damage [8,9].
In particular, anti-apoptotic signals associated with
alterations of the downstream Ras-MAPK-Erk and
PI3K-Akt-mTOR pathways contribute to chemo- and
radioresistance. If targeting these survival signals is
expected to be of therapeutic benefit in combination
with cytotoxic approaches, a well-designed inhibition of
some of these survival signals could have a more radical
effect and directly promote tumor destruction. Indeed,
some of the survival signals harbored by HER2 overex-
pressing cells might directly contribute to cancer pro-
gression by allowing cancer cells to survive to
constitutive death signals. The existence of such signals
is suggested, at least in part, by the fact that the kinase
cascade triggered by the hyperactivity of receptors of the
HER family can be “addictive” to cancer cells [10]. Such
apparent addiction seems to result from the fact that
hyperactivity of HER pathways has tumor promoting
(survival) effects, but also tumor suppressive (death pro-
moting) ones [11,12]. Death signals downstream of
EGFR signaling have been reported, but not fully
described in molecular details [10]. Moreover, it has
remained unknown whether similar signals are initiated
downstream of HER2. Investigating whether constitutive
death and compensatory survival signals exist in HER2
overexpressing cells is of importance, as it may lead to
the identification of a critical event in the HER2 net-
work that needs to be altered by current targeted thera-
pies, or that could be directly targeted without altering
the rest of the network with great therapeutic benefit.
An investigation of the roles played by the Bcl-2
family of proteins in the survival of HER2 overexpres-
sing cells may prove very useful to address this issue.
This family of interacting pr o t e i n sr e p r e s e n t sa ni n t e -
grating node towards which converge numerous death
and survival signals in mammalian cells, including these
induced by oncogenic signals [13]. Anti-apoptotic Bcl-2
homologues preserve mitochondrial integrity by oppos-
ing the activity of multi-domain pro-apoptotic Bcl-2
family members Bax and Bak, which display sequence
conservation throughout three Bcl-2 homology (BH)
domains (BH1-3), and that of their upstream effectors,
the BH3-only proteins (e.g. Bim, Puma, Bad...). This
occurs essentially by physical interactions between anti-
and pro-apoptotic members which allows the former to
negatively control the activation, and the activity, of
pro-apoptotic Bax and Bak (themselves essential actors
of the apoptotic response of mammalian cells to multi-
ple stimuli). Anti-apoptotic Bcl-2 homologues (e.g.
Bcl-2, Bcl-xL, Mcl-1) control the sensitivity to conven-
tional pro-apoptotic therapy of tumor cells. In certain
instances, their expression is necessary to maintain the
survival of cancer cells [14,15], indicating that they may
be required to counteract constitutive death signals.
There is substantial evidence that the balance between
anti- and pro-apoptotic proteins of the Bcl-2 family is
biased in favor of survival proteins during breast carci-
nogenesis. Most breast cancers arise from epithelial cells
that express Bcl-2, Bcl-xL and Mcl-1 [16,17], and
enhanced expression of these proteins is almost system-
atically found in transformed mammary epithelial cells.
Signaling pathways downstream of HER2 have numer-
ous anti-apoptotic effects on Bcl-2 family members
[18-20].
In this study, we investigated whether and how the
imbalance in favor of survival proteins of the Bcl-2
family, which is induced by the sustained activity of sig-
naling pathways downstream of HER2, contributes to
survival maintenance in HER2 overexpressing breast
cancer cells. We herein demonstrate that such cells
undergo apoptosis upon depletion of Mcl-1, and that
this Mcl-1 dependence is due to their constitutive
expression of the pro-apoptotic protein Bim. The latter
expression is a direct consequence of oncogenic signal-
ing, as it is due to mTORC1 dependent expression
of c-Myc, which occupies regions within the Bim
promoter.
Methods
Reagents, antibodies and siRNAs
The following primary antibodies were used for western
blotting: anti-actin from Millipore (mouse, MAB1501R),
anti-ß-tubulin from Sigma (mouse, T0198), anti-Bcl-xL
antibody from Transduction Lab. (rabbit, 610212);
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Santa Cruz (rabbit, B0410), anti-Puma from Calbiochem
(rabbit, PC686); anti-Bim from Chemicon International
(rabbit, 17003), anti-c-Myc from Cell Signaling (rabbit,
9402), anti-Foxo3A from Upstate (rabbit, 07-702), anti-
phospho-p70 S6 kinase (Thr 388) from Cell Signaling
(mouse, 9206). The following primary antibodies were
used in chromatin immunoprecipitation assays (ChIP):
anti-c-Myc (sc-764), anti-E2F1 (sc-193) from Santa Cruz
(USA). Horseradish peroxidase-conjugated antibodies
and enhanced chemiluminescence reagents were
obtained from Santa Cruz (USA). Novartis provided
RAD001. Unless indicated, all other reagents used in
this study were obtained from Sigma. The following siR-
NAs were used: si-control A from Santa Cruz (sc-
37007), si-Bcl-2 from Santa Cruz (sc-29214), si-Bcl-xL
from Dharmacon (L-003458-00), si-Mcl-1 from Ambion
(120644), si-Bim from Cell Signaling (6461), si-Puma
from Dharmacon (L-004380-00), si-Myc from Santa
Cruz (sc-29226), si-Foxo3A from Invitrogen (FOXO3a
Validated Stealth DuoPak)
Cell lines
BT474, SKBR3 and MCF7, obtained from ATCC, were
grown at 37°C with 5% of CO2 and humidified atmo-
sphere. BT474 and MCF7 cells were grown in RPMI-
1640 medium supplemented with 10% FBS (Fetal Bovine
S e r u m ) ,1 %g l u c o s e ,0 , 1 %i n s u l i n ,1 %N a - p y r u v a t e ,1 %
non essential amino acids, 5% peni streptomycin. SKBR3
were grown in Mc Coy’s 5A medium supplemented
with 10% FBS, 5% glutamine, 5% peni streptomycin.
The non-transformed mammary epithelial cell line
MCF10A was obtained from ATCC and grown in the
recommended culture medium.
Transient RNA interference and drug treatment
One day prior transfection, 2.10
5 cells/well were
seeded in 6-well plates with complete medium. Cells
were transfected with siRNA oligonucleotides using
Lipofectamine™ RNAiMax (InVitrogen) according to
the manufacturer instructions. Briefly, cells were
gently washed with PBS (Phosphate Buffered Saline)
before transfection with a mix containing OPTIMEM,
transfection reagent and 60 pmol of siRNA. After
5 hours of incubation, cells were gently washed with
PBS and fresh complete medium was added. When
applicable, a second transfection was performed 24
hours later following the same protocol. Adherent and
floating cells were collected 48 hours later to perform
western blot analysis or cell death investigations.
Treatment of BT474 cells with RAD001 (20 nM) was
performed on cells seeded in 6-well plates at 2.10
5
cells/well the day before and analysis was performed
as described above.
Western-blot analysis
Cells treated with RAD001 and/or the indicated siRNAs
were lysed as follows. Floating and adherent cells were
washed twice with cold-PBS. They were then lysed in
lysis buffer (1% SDS, 10 mM EDTA, 150 mM NaCl,
2 0m MT r i s - H C l ,p H8 . 1 ,1m Mphenylmethylsulfonyl
fluoride, 2 μg/ml leupeptin, 5 μg/ml aprotinin, 1 μg/ml
pepstatinA, 0.5 M NaF, 100 mM Na3VO4) and extracts
were sonicated six times for 15s each. Supernatants
were recovered by centrifugation at 12000 rpm for
10 min at 4°C.
To obtain tumor lysates, tumor tissue samples were
surgically collected from untreated patients and pro-
c e s s e di nt w op a r t sb yap a t h o l o g i s t :t h ef i r s tp a r tw a s
fixed in 10% neutral buffered formalin for standard his-
tological analysis and determination of the HER2 by
immunohistochemistry, and the second part was imme-
diately snap-frozen in liquid nitrogen and stored at
-180°C. This second part was crushed in liquid nitrogen
using a sterilized mortar. After three washes in PBS, the
samples were resuspended in a comparable volume of
lysis buffer and extracts were sonicated on ice for
15 minutes. Supernatants were recovered by centrifuga-
tion at 12000 rpm for 10 min at 4°C.
Lysates prepared as described above (70 μgo ft o t a l
proteins) were separated by SDS-PAGE (12% polyacrila-
mide gel) under reducing conditions followed by trans-
fer to a 0.45 μm PVDF membrane (Immobilon-P
transfer membrane, IPVH00010). Non-specific binding
was blocked by one hour incubation at room tempera-
ture in TBS-T (Tris Buffered Saline Tween, 25 mM
Tris, 150 mM NaCl, 0.05% Tween 20, pH = 8.0) con-
taining 5% (v/v) of blocking reagent (Western blocking
reagent, Roche, 11921681001). Primary monoclonal anti-
bodies were incubated for one hour at 37°C. After 3
washes with TBS-T, membranes were incubated with
peroxidase conjugated secondary antibody for one hour
at 37°C. Following 3 washes with TBS-T, blots were
revealed using the chemiluminescent blotting Substrate
Kit (Roche).
Cell death assays
Following the indicated treatments, cells were labeled
with the IOTest anti-APO2.7-PE (Beckman Coulter, PN
IM2088U) according to the manufacturer’si n s t r u c t i o n s .
Briefly, floating and adherent cells were washed once in
PBS, transferred in 96 well plates and washed twice
more in cold PBS. Cells were then resuspended in 500
μl of labeling mix diluted in PBS and incubated in the
dark for 15 minutes at RT. Cells were then washed in
PBS and either immediately analyzed by FACS or fixed
in 1% paraformaldehide for delayed FACS analysis.
APO2.7 positive cells were analyzed using the FL1
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CaliburTM cytofluorometer (BD). Annexin V staining
was performed similarly, according to the manufac-
turer’s instructions.
Mammosphere assays
BT474 cells treated with the indicated siRNA were
plated as single cells in ultra low attachment plates
(Corning) at low density (500 viable cells/cm
2). They
were grown in serum-free mammary epithelial cell
growth medium containing DMEM-F12 (Sigma) supple-
mented with B27 (Gibco) and MEGM singlequots
(Lonza France), as previously described [21]. Mammo-
sphere-forming unit were counted as number of mam-
mospheres ≥50 mm.
Chromatin Immunoprecipitation (ChIP) assays
BT474 cells treated or not with RAD001 (20 nM) were
washed and cross-linked with formaldehyde at room
temperature for 8 min essentially as previously described
[22]. Reaction was stopped with 10 ml of 125 mM glycin
solution. Cells were washed with cold PBS and lysed in
500 μl of lysis buffer (1% SDS, 10 mM EDTA, 50 mM
Tris-HCl pH 8.1, 1 mM PMSF, 5 mM NaF, 5 mM
Na3VO4, 2 μg/ml leupeptin, 5 μg/ml aprotinin, 1 μg/ml
pepstatin), and sonicated five times for 20 seconds each.
Supernatants were then recovered by centrifugation at
12 000 rpm for 10 min at 4°C, diluted once in dilution
buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl,
20 mM Tris-HCl pH 8.1) and subjected to one round of
immunoclearing for 2 h at 4°C with 2 μg of sheared sal-
mon-sperm DNA, and 20 μl of proteinG-agarose coated
with salmon sperm DNA (Millipore) (of 50% slurry).
Immunoprecipitation was performed overnight with
specific antibodies and IgG control, and then 2 μgo f
sheared salmon-sperm DNA and 20 μl of proteinG-agar-
ose coated with salmon sperm DNA (Millipore) (of 50%
slurry) were further added for 1 h at 4°C. Note that
immunoprecipitations were performed in the presence
of 1% Igepal CA-630. Immunoprecipitates were washed
sequentially for 10 min each in TSE I (0.1% SDS, 1%
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1,
150 mM NaCl), TSE II (0.1% SDS, 1% Triton X-100, 2
mM EDTA, 20 mM Tris-HCl pH 8.1, 500 mM NaCl),
and TSE III (250 mM LiCl, 1% NP-40, 1% deoxycholate,
1 mM EDTA, 10 mM Tris-HCl pH 8.1). Beads precipi-
tates were then washed once with TE buffer and eluted
once with 1% SDS, 100 mM NaHCO3. Eluates were
heated at 65°C for 6 hours to reverse the formaldehyde
cross-linking. DNA was precipitated using classical pro-
cedures. Real-time PCR was used for ChIP analysis and
quantification. The ChIP has been calculated as binding
to region of interest/IgG control, divided by binding to
negative control region/IgG control. The following
primers were used:
region -61/+50 of the Bim promoter: Forward 5’-
CAGTGATTGGGCGTAGGAG-3’, Reverse 5’-ACGCA-
GAGCTCCAACAAACT-3’; Control region -1701/-1399
of the Aurora A promoter For 5’-ACTCCAGATCCCT-
CAGCTTAACCA-3’ Rev 5’-CAAGTTATGGGACGGT-
GAACG-3’. All statistical analysis has been performed
with Graphpad Software.
Patient samples
As required by the French Committee for the Protection
of Human Subjects, informed consent was obtained
from study patients to use their surgical specimens and
clinicopathological data for research purposes, and the
local ethic committee approved protocols.
Statistical analysis of published expression data
The impact of HER2 status (as evaluated by immuno-
histochemistry) on the expression of 20 genes of the
Bcl-2 family was evaluated by means of Wilcoxon test.
When the evaluation was performed in a “probe-match-
ing” way, 2 pooled published cohorts for which Affyme-
trix data were available [23,24] were used after their
conversion to a common scale. In a “gene-matching
approach” the evaluation was performed on a larger
pool obtained by merging 5 genomic published cohorts
[23-27]. If multiple probes corresponded to a same
gene, the median of probes was taken.
Results
Mcl-1 is highly expressed in HER2 overexpressing cancers,
and is required to maintain the survival of HER2
overexpressing cells in vitro
The HER2 amplified BT474 breast cancer express detect-
able levels of the main anti-apoptotic Bcl-2 homologues
Bcl-xL, Bcl-2 and Mcl-1 (Figure 1A). We investigated
whether any of these proteins play a crucial role in main-
taining the viability of BT474 cells in vitro using a RNA
interference approach based on the transfection of small
interfering RNAs (siRNA) targeting Bcl-xL, Bcl-2 or Mcl-
1. Transfection with control siRNA did not impact on
the expression of these proteins compared to that
found in non-transfected cells (Figure 1A). In contrast,
transfection of BT474 cells with the targeted siRNA
led to the selective down regulation of the targeted
proteins 48 hours after treatment.W ea n a l y z e dt h e
consequence of Bcl-xL, Bcl-2 and Mcl-1 depletion, under
these conditions, on the viability of BT474 cells. We mea-
sured the expression, by the transfected cells, of the
APO2.7 antigen, whose expression is restricted to dying,
apoptotic cells. As shown in Figure 1B, knock down
of Mcl-1 expression by RNA interference lead to the
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contrast, depletion of either Bcl-xL or Bcl-2 did not
induce apoptosis in BT474 cells. Induction of cell death,
and of apoptosis, by Mcl-1 depletion in BT474 cells
was also confirmed by a trypan blue staining proce-
dure and by Annexin V staining followed by flow
cytometry analysis (Additional File 1). Thus, Mcl-1 is
specifically involved in preventing BT474 cells from spon-
taneously undergoing apoptosis.
Interestingly, we found that this feature of “Mcl-1
dependence” was displayed by another HER2 overex-
pressing cell line, SKBR3, as transfection with Mcl-1
siRNA was sufficient to induce rates of apoptosis in
these cells also (Figure 1C and Additional File 2). In
contrast, transfection with Mcl-1 siRNA, under the
same conditions, had no detectable effect on the viability
of ER positive MCF7 cells, that do not overexpress
HER2 (Figure 1C) despite down regulation of Mcl-1
(Additional File 2). Notably, expression levels of Mcl-1
in the three cell lines was high compared to that
f o u n di nt h en o nt r a n s f o r m e dm a m m a r ye p i t h e l i a l
cell line MCF10A (Additional File 3), indicating that
signaling pathways leading to enhanced expression of
Mcl-1 are active in transformed mammary epithelial
cells, and in HER2 overexpressing ones in particular.
Transformed mammary epithelial cells, including
established breast cancer cell lines such as BT474 cells
[28], exhibit an inherent phenotypic plasticity and har-
bor a subpopulation of cells with features of cancer
initiating cells (CIC). The latter cells, which are charac-
terized by numerous parameters, including their ability
to form spherical colonies in non-adherent culture con-
ditions (mammospheres), were frequently described as
being resistant to cell death induction by numerous sti-
muli [29]. This suggests that they may rely on survival
signals distinct from these that are critical for the rest of
the population. We thus investigated whether the Mcl-1
dependence of BT474 cells revealed above (in assays
performed on the bulk population) applies to the subpo-
pulation of CICs. To test this, we reasoned that, if
BT474 CICs are Mcl-1 dependent, then a diminished
ability to form mammospheres should be observed in a
population of BT474 that has been depleted in Mcl-1.
The ability of BT474 cells to form mammospheres
after transfection with siRNAs was thus evaluated.A s
shown in Figure 2, the ability of Mcl-1 depleted BT474
cells to form mammospheres was significantly decreased
compared to that of the same cells treated with a con-
trol siRNA. In contrast, Bcl-xL or Bcl-2 knock down
was insufficient by itself to affect mammosphere for-
mation by BT474 cells (Figure 2). Taken together,
these data indicate that the HER2 overexpressing BT474
cells require Mcl-1 to survive in vitro, and that this
Mcl-1 dependence extends to their subpopulation of
CICs.
To investigate whether pathways driving Mcl-1 expres-
sion are specifically active in HER2 overexpressing can-
cers, compared to other breast cancers, we analyzed the
expression of 20 pro- and anti-apoptotic Bcl-2 family
members from published gene-expression profiles of
breast cancer patients. We based this analysis on studies
in which the HER2 status of each tumor was available
and had been evaluated by immunohistochemistry,
Figure 1 RNA interference mediated knock-down of Mcl-1
induces cell death in HER2 overexpressing cells. BT474 cells
were left untreated or transfected with control siRNA, Bcl-xL siRNA,
Bcl-2 siRNA or Mcl-1 siRNA as indicated. (A) Down regulation of the
targeted proteins 48 hours after transfection was confirmed by
western blot analysis, using tubulin as a loading control. (B) Forty
eight hours after transfection, apoptosis was assessed by Apo 2.7
staining and FACS analysis as described in Materials and Methods.
Data represented (% of Apo2.7 positive cells) are the means +/-
standard errors of three independent experiments. p-values were
assessed using a Student’s t test. (C) Experiments were performed as
described in B, using HER2 overexpressing SKBR3 cells, and ER
expressing MCF7 cells, as indicated. Data are mean ± se of the
indicated number of independent experiments. p-values were
assessed using a Student’s t test
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rays. Two studies corresponded to these criteria, allowing
to investigate expression profiles of 41 HER2 overexpres-
sing tumors and 170 HER2 - ones (Table 1). Our evalua-
tion was performed in a “probe-matching” way, using the
2 pooled aforementioned cohorts. Regarding the expres-
sion of anti-apoptotic genes (pro-apoptotic ones are
evoked below), this evaluation revealed a statistically sig-
nificant enrichment (that is, a statistically significant
higher expression), in HER2 overexpressing breast
tumors compared to other breast tumors, in one MCL1
specific probe and also in one BCL2L1 (Bcl-xL) one
(Table 1). In contrast, other breast tumors appeared sta-
tistically enriched for three BCL2 specific probes (Table
1). Interestingly, when the evaluation was performed on a
larger pool obtained by merging the two previously
described cohorts with 3 additional genomic published
cohorts (see Materials and Methods), using a “gene-
matching” approach, an enrichment in MCL1 expression
in HER2 overexpressing tumors (455 HER2- versus 71
HER2+, p = 0,0156), and in BCL2 in the other ones (216
HER2- versus 52 HER2+, p = 0,0145) was also found. In
contrast, enrichment in BCL2L1 (268 HER2- versus 55
HER2+,) was no longer found. These molecular profiling
analyses are mostly consistent with the notion that
mechanisms leading to Mcl-1 transcription and expres-
sion are highly active in HER2 overexpressing breast
cancers.
Figure 2 Mcl-1 knockdown negatively impacts on
mammosphere formation by BT474 cells. BT474 cells were
transfected with control or the indicated siRNA, as described in
Figure 1. One day later, the resulting cells were plated in non-
adherent conditions under mammosphere medium, as described in
Methods. Mammosphere formation was analyzed by microscopy for
(A) and the number of mammospheres formed per dish was
enumerated (B) two days later. Data are mean ± se of 3
independent experiments normalized to data obtained with
transfection with a control siRNA.
Table 1 Impact of HER2 status on the expression of Bcl-2
family members in mammary tumors
Probe Gene pValue Enrichment in HER2+
P_1861_at BAD 0,0294 -
P_203728_at BAK1 ns ns
P_208478_s_at BAX ns ns
P_211833_s_at BAX ns ns
P_211692_s_at BBC3 ns ns
P_203685_at BCL2 < 0.0001 -
P_207004_at BCL2 0,0157 -
P_207005_s_at BCL2 0,0311 -
P_203684_s_at BCL2 ns ns
P_205681_at BCL2A1 ns ns
P_212312_at BCL2L1 0.0054 +
P_206665_s_at BCL2L1 ns ns
P_215037_s_at BCL2L1 ns ns
P_221320_at BCL2L10 ns ns
P_222343_at BCL2L11 0.0061 +
P_208536_s_at BCL2L11 ns ns
P_217955_at BCL2L13 ns ns
P_221241_s_at BCL2L14 ns ns
P_209311_at BCL2L2 ns ns
P_211725_s_at BID 0,0086 +
P_204493_at BID ns ns
P_205780_at BIK 0.016 ns
P_221454_at BOK ns ns
P_206864_s_at HRK ns ns
P_206865_at HRK ns ns
P_214056_at MCL1 0,0097 +
P_200796_s_at MCL1 ns ns
P_200797_s_at MCL1 ns ns
P_200798_x_at MCL1 ns ns
P_214057_at MCL1 ns ns
P_204285_s_at PMAIP1 0,0005 -
P_204286_s_at PMAIP1 < 0.0001 -
The impact of HER2 status (evaluated by immunohistochemistry) on the
expression of 20 genes of the Bcl-2 family was evaluated as described in
Methods. The cohort contained 41 HER2+ and 170 HER2- ones. + and -
indicate an enrichment and an impoverishment, respectively, in the HER2
overexpressing cohort. P values were assessed by a Wilcoxon test. Pro-
apoptotic genes are shown in bold.
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BT474 cells is due to constitutive expression of
pro-apoptotic Bim
We investigated the molecular basis of the signal(s) that
render(s) Mcl-1 necessary for the viability of HER2-
overexpressing cells. Bcl-2 homologues promote survival
in great part by counteracting pro-apoptotic counter-
parts, Bax/Bak and their upstream effectors the BH3-
only proteins. Some BH3-only proteins, such as Bid,
BIM or PUMA interact with all known anti-apoptotic
Bcl-2 members, and activate Bax/Bak directly. They are
therefore good candidates as proteins that can initiate
death signals that make anti-apoptotic proteins (in our
case, Mcl-1) required for survival. This is particularly
true for Bim and Puma, that activate Bax/Bak in their
native form, whereas cleavage of Bid is required for it to
exert its pro-apoptotic activity [30].
We found that BT474 cells express detectable levels of
Puma and of Bim whether cells were grown under con-
trol conditions or transfected with control, scramble siR-
NAs (Figure 3A and Additional File 4). In contrast,
these cells expressed barely detectable levels of Noxa,
a BH3-only protein which functions as a selectiove
inhibitor of Mcl-1 (Additional File 4). Regarding Bim, it
has to be noted that we essentially detected its Bim
Extra-Long (EL) form, whereas the Long (L) and Short
(S) forms were less expressed in these cells (Figure 3).
To investigate whether Bim or Puma play an active role
in the Mcl-1 dependence of BT474 cells, these cells were
transfected with control, Bim or Puma siRNA, which
down regulated efficiently the targeted proteins (Figure
3A), prior to their transfection with Mcl-1 siRNA and
investigation of cell death. Of note, neither Bim nor
Puma siRNA affected cell viability by themselves (Addi-
tional File 1and data not shown). Bim depletion robustly
prevented cell death induced by transfection with Mcl-1
siRNA, as measured by APO2.7 staining (Figure 3B)o r
by Annexin V staining (Additional File 1), indicating
that this pro-apoptotic protein plays a major role in the
Mcl-1 dependence of BT474 cells. In contrast, PUMA
depletion had a much less pronounced and consistent
effect on Mcl-1 knock down induced cell death (Figure
3A and Additional File 1).
We investigated whether Bim contributes to the Mcl-1
dependence of the subpopulation of BT474 that are cap-
able of forming mammospheres. Bim depletion had no
impact in itself on mammosphere formation by BT474
cells. However, it abrogated the ability of Mcl-1 knock
down to decrease the number of mammospheres formed
by BT474 cells (Figure 3C). This is strong support to the
notion that the Mcl-1 dependence of BT474 CICs also is
due to Bim expression.
It rises from above that constitutive expression of Bim
may contribute to render Mcl-1 necessary for the
survival of HER2 overexpressing tumors. To analyze
whether mechanisms leading to Bim transcription are
particularly at stake in HER2 overexpressing tumors, we
went back to our investigation of published gene-expres-
sion profiles of breast cancer patients using a probe-
matching approach as described above. As shown in
Table 1, we found a statistically significant enrichment,
in HER2 overexpressing breast tumors compared to
Figure 3 Expression of pro-apoptotic Bim is required for
induction of cell death and decrease in mammosphere
formation by Mcl-1 knock down. BT474 cells were transfected
with control siRNA, Bim siRNA, PUMA siRNA and/or Mcl-1 siRNA as
indicated. (A) Western blot analysis was performed to confirm the
down regulation of the targeted proteins by each of the indicated
siRNA. (B) Apoptosis was assessed 48 hours later by Apo 2.7 staining
as described in Figure 1. Data are mean ± se of three independent
experiments. They are expressed as a percentage of cell death
obtained after Mcl-1 siRNA transfection of cells that had been
transfected with control siRNA (46% ± 5.2%). p-values were
assessed using a Student’s t test. (C) Mammosphere formation by
BT474 cells transfected with the indicated siRNA was evaluated as
described in Figure 2. Data are mean ± se of 3 independent
experiments normalized to data obtained with transfection with a
control siRNA.
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probe. Regarding pro-apoptotic genes, a statistical
enrichment in one BID specific probe and in one BIK
specific probe was also found (Table 1). In contrast,
other breast tumors appeared statistically enriched for
two PMAIP1 (Noxa) specific probes and for one BAD
specific one (Table 1). While this tends to suggest that
pathways leading to Bim transcription might be more
active in HER2 overexpressing breast cancers, this
should nevertheless be taken cautiously. Indeed, we did
not confirm a statistical enrichment for Bim expression
in HER2 overexpressing cancers by our gene-matching
approach involving 5 cohorts (described above), even
though enrichment for BID and BIK and impoverish-
ment for BAD and NOXA were confirmed.
In an independent attempt to confirm that HER2
overexpressing tumors express Bim, we prepared lysates
from five tumors that had been diagnosed as HER2
overexpressing ones by immunohistochemistry and per-
formed western blot analysis. As shown in Figure 4,
these lysates expressed detectable levels of anti-apoptotic
Bcl-2, Bcl-xL and Mcl-1. They also expressed detectable
levels of Bim. Most importantly here, we picked these
samples because they correspond to tumors that had
received no treatment prior surgery. The expression of
pro-apoptotic Bim detected does not, therefore, result
from stress induced by treatment, but is more likely to
result from signals that are inherent to the biology of
these tumors.
c-Myc contributes to Bim expression and Mcl-1
dependence of BT474 cells
We investigated which signaling pathways might contri-
bute to Bim expression in BT474 cells. Foxo3a is a
member of the Foxo class of the forkhead family of
winged helix transcription factors, which was reported
to directly induce the transcription of Bim, in particular
in some breast cancer cells [19]. However, a RNA inter-
ference approach that successfully down regulated
Foxo3A expression in BT474 cells (Figure 5A) had no
discernible effect on constitutive Bim protein expression
(Figure 5B), ruling out that Foxo3A activity is responsi-
ble for this constitutive expression.
c-Myc is a transcription factor that resembles tran-
scription factors of the basic helix-loop-helix leucine
zipper (bHLH-LZ) family. It is a major regulator of cell
proliferation but it is also capable of promoting apopto-
sis. In particular, it was reported to induce Bim in cer-
tain settings ([31] and see below). We used a RNA
interference approach to specifically down-regulate c-
Myc in BT474 cells (Figure 5A) and we found that it
induced a significant decrease in the expression of Bim
in the resulting cells (Figure 5B).
To investigate whether c-Myc is involved in the inher-
ent Mcl-1 dependence of BT474 cells, these cells were
transfected with control or c-Myc siRNA, prior to their
transfection with Mcl-1 siRNA and investigation of cell
death as described above. Of note, c-Myc siRNA had no
impact on cell viability by itself (data not shown). As
shown in Figure 5C, decreased c-Myc expression dimin-
ished cell death induced by transfection with Mcl-1
siRNA, indicating that this transcription factor contri-
butes to the Mcl-1 dependence of BT474 cells.
Decrease of c-Myc expression upon inhibition of mTORC1
diminishes Bim expression levels and mitigates the Mcl-1
dependence of BT474 cells
In HER2-overexpressing cells with high Akt activity,
mTORC1 downstream of Akt is expected to actively
contribute to c-Myc expression [6]. Thus, Bim expres-
sion in such cells may directly result from oncogenic
signaling. To confirm this notion, we treated BT474
cells with the mTORC1 inhibitor RAD001, under condi-
t i o n st h a tp r o v e ds u f f i c i e n tt op r e v e n tt h e i rg r o w t h[ 7 ] ,
arrest these cells in the G1 phase of the cell cycle
(data not shown) and prevent phosphorylation of S6K
Figure 4 HER2-amplified mammary tumors express detectable
levels of Bim. Tumor lysates were prepared and analyzed by
western blotting as described in Materials and Methods.
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induce significant apoptosis rates in BT474 cells (evalu-
ated by APO2.7 staining as described above, Figure 6B)
and had no detectable impact on Mcl-1 expression
(Figure 6A). In contrast, this treatment lead to a
decrease in c-Myc expression (Figure 6A). Coinciden-
tally, RAD001 treatment significantly decreased Bim
expression in BT474 cells (Figure 6A).
Since c-Myc both affects Bim expression in BT474
cells as well as their Mcl-1 dependence, we then ana-
lyzed whether RAD001 treatment, which impacts on
Bim expression, also impacts on such dependence.
Cells were treated with RAD001 or not prior to their
transfection with control or Mcl-1 siRNA, and cell
death rates were analyzed as described above. As shown
in Figure 6C, RAD001 treatment did not enhance cell
death rates induced by Mcl-1 siRNA, indicating that
RAD001 has no pro-apoptotic effect even in Mcl-1
depleted BT474 cells. Instead, we found that RAD001
significantly prevented cell death induced by Mcl-1
siRNA. Western blot analysis( F i g u r e6 D )s h o w e dt h a t
RAD001 treatment did not interfere with the ability of
Mcl-1 siRNA to down regulate Mcl-1 and that, conver-
sely, RAD001 treatment was still efficient (as judged by
its effect on the phosphorylation of S6K) in Mcl-1
depleted cells. Moreover, RAD001 treatment decreased
Bim expression in cells treated with a control siRNA
and in Mcl-1 depleted cells (Figure 6D). In contrast, the
Figure 5 c-Myc expression in BT474 cells impacts on Bim
expression and Mcl-1 dependence. BT474 cells were transfected
with control siRNA, Foxo3A siRNA or c-Myc siRNA, as indicated. 48
hours later, western blot analysis was performed to confirm the
effect of each siRNA on the expression of the targeted proteins and
on Bim (EL), (L-) and (S), as indicated (A-B). In (C), BT474 cells were
transfected with control siRNA, c-Myc siRNA, and/or Mcl-1 siRNA as
indicated and apoptosis was assessed 48 hours later as described in
Figure 1. Data are mean ± se of three independent experiments.
They are expressed as a percentage of cell death obtained after
Mcl-1 siRNA transfection of cells that had been transfected with
control siRNA (42.4% ± 6.8%). p-values were assessed using a
Student’s t test.
Figure 6 Treatment of BT474 cells with the mTORC1 inhibitor
RAD001 decreases Myc and Bim expression and mitigates Mcl-
1 dependence. (A-B) BT474 cells were treated with 20 nM RAD001
for 72 hours. (A) Western blot analysis was performed to document
the effect of RAD001 treatment on Mcl-1, c-Myc and Bim
expression. (B) Cell death was assessed by Apo 2.7 staining as
described in Materials and Methods. Data are mean ± se of three
independent experiments. p-values were assessed using a Student’s
t test. (C) BT474 cells were treated with 20 nM RAD001 or left
untreated, as indicated. 24 hours later, cells were transfected with
control or Mcl-1 siRNA and put back into control or RAD001
containing complete medium. Apoptosis was assessed 48 hours
later by Apo 2.7 staining as described in Figure 1. Data are mean ±
se of the indicated number of independent experiments. p-values
were assessed using a Student’s t test. (D) Western blot analysis was
performed to document the effects of RAD001 treatment and of
Mcl-1 siRNA on the phosphorylation of p70S6K and on Mcl-1, Bim
and XIAP expression, using ß-tubulin as a loading control.
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tein whose expression was reported to be enhanced
by mTORC1 inhibition in some cases [32] were left
unchanged by RAD001 treatment (Figure 6D). Thus,
these data reveal a genuine anti-apoptotic effect exerted
by RAD001 treatment in BT474 cells, which allows
them to survive even when Mcl-1 is depleted and which
correlates with a decrease in Bim expression.
c-Myc occupies regions of the Bim promoter by an
mTORC1 dependent process
In a last series of experiments, we analyzed whether the
RAD001 sensitive, c-Myc dependent expression of Bim
we detected in BT474 cells directly ensued from tran-
scriptional regulation of Bim by c-Myc, id est from
mTORC1 dependent occupancy of regions of the Bim
promoter by this transcriptional factor. Using the UCSC
genome browser (http://genome.ucsc.edu), we noticed
that ChIP-on-chip experiments have already suggested
that c-Myc can potentially bind to the BCL2L11 (Bim)
promoter in HeLa cells. Moreover, Ouyang and colla-
borators have shown by ChIP-seq assays that c-Myc and
its homologue N-Myc can be found associated with this
gene in embryonic stem cells [33]. Consistent with these
findings, transcription factor recognition site analysis of
the BCL2L11 gene by Matinspector software http://
www.genomatix.de showed the presence of a large num-
ber of potential c-Myc binding sites (Figure 7A).
To determine if c-Myc binds to the Bim promoter, we
analyzed its recruitment by chromatin immunoprecipita-
tion assays (ChIP) in BT474 cells. Results presented in
Figure 7B show that c-Myc is recruited to the initiation
transcription site of BCL2L11 gene. Of note, we found
this to be associated with the binding of histone 3 (H3)
acetylation (K9) and that of RNA polymerase II (data
not shown), which is indicative of gene transcription.
Interestingly, we also noticed the recruitment of
the E2F1 transcription factor on this gene. Following
mTORC1 inhibition by RAD001 treatment, as expected
from the decrease of c-Myc expression under these con-
ditions, an inhibition of c - M y cb i n d i n gt ot h eB i m
promoter was observed (Figure 7B). This correlated with
a loss of the transcription indicators (data not shown).
In contrast, E2F1 binding was not affected following
RAD001 treatment suggesting that RAD001-mediated
inhibition of Bim expression is E2F1 independent.
Altogether, these data indicate that mTORC1 pro-
motes Bim expression by stabilizing c-Myc on BCL2L11
promoter in the HER2-overexpressing breast cancer cell
lines BT474.
Discussion
We used, in this study, BT474 cells that overexpress
HER2/neu, and in which signaling downstream of this
member of the EGF receptor family is highly active. Our
results establish that, despite the potent and numerous
survival signals that are associated with HER2 activity,
these cells rely on the expression of a single anti-apop-
totic protein for their survival, as the down regulation of
Mcl-1 is sufficient to induce significant rates of sponta-
neous apoptosis in these cells. Mcl-1 appears to be cru-
cial even for the subpopulation of BT474 that have
features of cancer initiating cells, as its depletion signifi-
cantly reduces the number of mammospheres these cells
can form. Since the co depletion of pro-apoptotic Bim
(which reduces cell death rates induced by Mcl-1 deple-
tion as discussed below) mitigates the effects of Mcl-1
knock down on mammosphere formation, these effects
most likely result from the induction of cell death in
sphere forming cells. We cannot formally rule out, how-
ever, that Mcl-1 contributes to the biology of cancer
initiating cells by mechanisms other than regulation of
cell survival stricto sensu. This aspect is currently being
investigated in our laboratory.
Given the role played by Mcl-1 in maintaining the
survival of HER2 expressing cells, and in maintaining a
significant pool of cancer initating cells among them,
pathways that lead to the expression of the anti-apopto-
tic protein Mcl-1 are expected to contribute to the
pathogenesis of HER2 amplified mammary tumors. Con-
versely, pharmacological manipulations of these path-
ways may be of therapeutic benefit. Our investigation of
published expression data hint on a selective enrichment
for Mcl-1 trancripts in HER2 amplified mammary
tumors compared to other mammary tumors. Thus,
pathways that positively impact on the transcription of
Mcl-1 may be particularly active in HER2 amplified
tumors, either because they are directly triggered by this
pathway or because their secondary activation contri-
bute to the progression of this malignancy. One such
pathway might be the one that relies on STAT3 activity
which was shown to promote Mcl-1 transcription and
to be activated in response to ligands that activate
growth factor receptors with tyrosine kinase activity,
including HER2 [34-36].
Mcl-1 protein and mRNA both have short half-lives.
Mcl-1 mRNA has a G+C-rich 5’UTR and its translation
is expected to be preferentially increased when the activ-
ity of EIF4F is elevated [37]. Our demonstration of a key
role of Mcl-1 in the survival of HER2-amplified cells
might thus have provided one rationale for the use of
the mTORC1 inhibitor RAD001 against this malignancy.
Our results nevertheless show that an impact of
RAD001 on the viability of HER2-amplified cells, via an
effect on Mcl-1 expression, may not be guaranteed.
Concentrations of RAD001 that are sufficient to inhibit
the growth and cell cycle progression of BT474 cells are
indeed inefficient at inducing apoptosis and at down
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of mTORC1, in conditions in which it is sufficient to
promote cell cycle arrest and the down regulation of
proteins involved in cell cycle control (such as c-Myc),
does not affect Mcl-1 expression, is currently unclear.
One possibility is that RAD001, like rapamycin, only
partially inhibits mTORC1, affecting phosphorylation of
rpS6 but leaving phosphorylation of 4EBP1 relatively
unaltered. Increases in Mcl-1 protein levels downstream
of oncogenic Akt signaling in thymocytes were shown
to result from EIF4E hyper activation, through a process
that is specific to the 4EBP1 arm of oncogenic mTOR
Figure 7 Myc associates with the Bim promoter by a RAD001 dependent process in BT474 cells. (A) Schematic representation of the
potential Myc binding sites of the BCL2L11 promoter. (B) BT474 cells were treated (2, 4, 6) or not (1, 3, 5) with RAD001, soluble chromatin was
immunoprecipitated with anti-Myc (3, 4) or anti-E2F-1 antibodies (5, 6) and DNA samples were then amplified using primers that cover the -61/
+50 region of the BCL2L11 promoter. IgG immunoprecipitations were used as controls (1, 2). Data are mean ± sd of 4 independent experiments
normalized to data obtained with control IgG immunoprecipitations. p-values were assessed using a Student’s t test.
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More potent inhibition of mTORC1 might thus impact
on Mcl-1 expression in BT474 cells. We cannot rule
out, moreover, the involvement of mechanisms capable
of enhancing the stability of the Mcl-1 protein, such as
the one that relies on the deubiquitinating enzyme
USP9X [39], which is also involved in HER2 stability
[40]. The resistance of Mcl-1 expression to mTORC1
inhibition by compounds that are used in the clinic
revealed here, suggests that strategies aiming at inhibit-
ing Mcl-1 transcription or at inhibiting the protein itself
might constitute a more efficient, and reliable, approach
than these that target its translation.
RAD001 treatment of BT474 cells not only leaves cell
viability unaltered, but it protects cells against death
induced by Mcl-1 depletion. Thus, active, RAD001 sen-
sitive dependent death signals are involved in installing
Mcl-1 dependence. It has been established, over the
last decade, that the pro-apoptotic multidomain pro-
teins Bax and Bak play a major role in the apoptotic
response of mammalian cells. Moreover, numerous
data have converged towards the notion that the BH3
domains of some “activator” BH3-only proteins (that of
Bid, Bim and Puma) have the innate ability to interact
with these proteins and to activate them. Thus, anti-
apoptotic proteins allow cell survival by binding to
their pro-apoptotic counterparts, thereby preventing a
low affinity but high efficiency interaction between
“activator” BH3-only proteins and multidomain pro-
teins to occur and to kill cells. In support to this, we
recently established that the ability of PUMA to acti-
vate Bax renders cells that constitutively express it
dependent upon the sustained BH3-binding activity of
Bcl-2 and Bcl-xL for survival [15]. Our observations
that cell death rates induced by Mcl-1 depletion in
BT474 cells are decreased by the co depletion of Bim
a r ea l s om o s t l yc o n s i s t e n tw i t ht h i sv i e w .N u m e r o u s
studies (in particular in lung and breast cancer cells,
[41]) have hinted on a role of the Bim/Mcl-1 balance
in the control of survival, but very few have shown, as
it is the case here, that the mechanism involved relies
on Mcl-1 counteracting the ability of Bim to promote
cell death, rather than the ability of Bim to erode the
cytoprotective effect of Mcl-1.
It rises from above that signaling pathways that lead to
the expression and the stability of Bim will actively con-
tribute to render Mcl-1 expression required for survival.
Our finding that Bim expression can be detected in
l y s a t e st h a tw e r ep r e p a r e df r o m5H E R 2 - a m p l i f i e d
tumors that had received no treatment indicate that
such pathways are active in this malignancy. Mechan-
isms that regulate Bim transcription in particular might
be effective, as suggested by the possible enrichment
for some Bim transcripts in HER2 amplified tumors
revealed by our investigation of publicly available
expression data from breast cancer. Our finding that
RAD001 negatively regulates Bim expression indicate
that mTORC1, which plays an important oncogenic role
in HER2 amplified tumors, might contribute to this
expression. The pro-apoptotic role our data attribute to
the mTOR pathway is somewhat reminiscent to that
reported for its downstream kinase S6K in hepatocytes,
where S6K contributes to Bim expression [42]. Our data
suggest that mTORC1 favors Bim expression by control-
ling the expression and the activity of c-Myc, and that
this transcription factor is involved is the constitutive
expression of Bim in BT474 cells. The results of our
ChIP assays indicate that RAD001 sensitive c-Myc
might be directly involved in the transcription of Bim in
BT474 cells. As the mTOR pathway is frequently active
in HER2 overexpressing breast cancers and regulates c-
Myc activity, our results imply that the corresponding
tumor cells might frequently express constitutive Bim.
This constitute a molecular vulnerability that renders
the sustained anti-apoptotic activity of Mcl-1 necessary
for survival. Thus, one promising approach for the treat-
ment of HER2 overexpressing breast cancers might
be one that relies on the use of inhibitors of the anti-
apoptotic activity of Mcl-1.
Conclusions
Our work provides strong support to the notion that
some tumor cells might depend upon a limited number
of anti-apoptotic Bcl-2 like proteins (Bcl-2L) for their
survival. It establishes that this “Bcl-2L dependence”
extends to HER2 amplified tumors, and that, in these
tumors, it relies, at least in part, on the interconnected
pathways that lead to pro-apoptotic Bim and anti-apop-
totic Mcl-1 expressions. This implies that current tar-
geted approaches need to influence the balance between
Bim and Mcl-1 to efficiently affect cancer cell survival.
It also implies that novel strategies (such as these based
on the use of Bcl-2 homologues inhibitors) that directly
act upon this balance without interfering with the rest
of the HER2 network are a promising alternative for the
treatment of this disease.
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Additional file 1: Bim dependent induction of cell death by Mcl-1
knock down in BT474 cells. Top panel. BT474 cells were transfected
with the indicated siRNA as described in Figure 1 and cell death was
evaluated by a trypan blue procedure. Data are mean ± se of three
independent experiments. Middle panel. BT474 cells were transfected
with control siRNA, Bim siRNA, PUMA siRNA and/or Mcl-1 siRNA as
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Page 12 of 14indicated and Annexin V expression was analyzed 48 hours later. Data
are mean ± se of three independent experiments. Bottom panel Western
blot analysis was performed to confirm Mcl-1 down regulation in cells
transfected with Mcl-1 siRNA together with control (ctr), Bim or Puma
siRNA.
Additional file 2: Down regulation of Mcl-1 by siRNA transfection of
MCF7 and SKBR3 cells. The indicated cells were transfected with the
indicated siRNA and western blot analysis of Bim and Mcl-1 was
performed 48 hours later using tubulin as a loading control.
Additional file 3: Expression of Mcl-1 and of Bim in BT474, SKBR3,
MCF7 and MCF10A cells. Western blot analysis was performed using
lysates from the indicated cells.
Additional file 4: Lack of effect of control siRNA transfection on the
expression of Mcl-1, Bim, Noxa and Puma in BT474 cells. BT474 cells
were left untreated or transfected with a control siRNA and western blot
analysis was performed 48 hours later, using tubulin as a loading control.
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